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Abstract: Poor treatment adherence is problematic in many therapy areas, including multiple 
sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of 
which require frequent parenteral administration. Current first-line therapies are two formulations 
of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of 
treatment is common, particularly in the first few months after initiation. Although the true effect 
of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy. 
Many factors influence a patient’s adherence to treatment, including the patient’s MS subtype 
and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the 
prescribed medication, and adverse events associated with MS therapy. This article summarizes 
the barriers to adherence to MS therapies, and discusses patient management strategies that can be 
employed to encourage adherence. Future advances in the field of MS treatment will be explored, 
including the development of orally administered drugs, which may enhance adherence.
Keywords: multiple sclerosis, adherence, compliance, interruption, adverse events, efficacy, 
tolerability, management
Introduction
The World Health Organization (WHO) defines adherence as “The extent to which 
a person’s behavior – taking medication, following a diet, and/or executing lifestyle 
changes, corresponds with agreed recommendations from a health care provider.”1 
Adherence to treatment regimes is essential to ensure patients receive the maximum 
benefit from their treatment and also to make sure that treatment is cost-effective. 
Nonadherence or poor adherence to therapy can lead to poor outcomes or treatment 
failure, and to increased costs.1
The WHO considers poor adherence to medication to be a serious problem world-
wide. In developed countries, adherence among patients suffering from chronic diseases 
is as low as 50%. This figure is probably even lower in developing countries.1 For 
example, adherence to oral anticancer agents can be as low as 20%,2 and adherence 
to some oral treatments for diabetes is only 36%.3
This article will explore the issue of adherence to treatment for multiple sclerosis (MS). 
The barriers to full adherence encountered by patients and clinicians will be described, 
and strategies that may be used to improve rates of adherence will be discussed.
Adherence to MS therapy
MS is a chronic demyelinating autoimmune disorder of the central nervous system. 
It is estimated to affect 2.5 million people worldwide, and is the most common Patient Preference and Adherence 2010:4 
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cause of neurological disability among young people.4 MS 
has several clinical forms. Patients are most often initially 
diagnosed with relapsing–remitting MS with new symptoms 
appearing during discrete acute attacks (relapses) between 
which the patient regains some or all neurological function, 
although residual disability tends to accumulate over time. 
Many patients with relapsing–remitting MS go on to develop 
secondary progressive MS, which is characterized by pro-
gressive neurological decline, over which acute relapses 
may be superimposed.5
MS is currently incurable, although a variety of treat-
ment approaches are available, including physiotherapy, 
psychotherapy, and management strategies to mitigate the 
symptoms of MS. Immunomodulatory agents are available 
that can modify the course of the disease by altering the 
pathological immune responses underlying MS. Treat-
ment with these disease-modifying drugs (DMDs) aims 
to reduce the rate of acute neurological attacks, and can 
delay disability progression. First-line treatment options 
for MS currently consist of four immunomodulatory drugs: 
interferon (IFN) beta-1a, administered subcutaneously (sc) 
3 times weekly; IFN beta-1a, administered intramuscularly 
(im) once weekly; IFN beta-1b administered sc every other 
day; and glatiramer acetate administered sc once daily. All 
of these drugs have to be administered parenterally on a 
regular basis, and are associated with injection-related 
side-effects such as injection-site reactions, which may 
influence adherence, particularly during the first few months 
of treatment. The second line of treatment for MS includes 
immunosuppressant agents such as cyclophosphamide and 
mitoxantrone. While these agents have been shown to be 
effective in MS therapy, they have widespread effects on the 
immune system and suppress both beneficial and harmful 
immune responses.6 These drugs tend to be used only in 
patients who do not respond to first-line therapy, and poten-
tial toxicity issues make them a short-term option. Natali-
zumab is a newer immunosuppressant, which has a more 
targeted activity against pathological immune responses. 
Again, because of the potential for serious side-effects, 
natalizumab is generally only recommended for patients 
with highly active MS who show an inadequate response 
to first-line therapy.7
Studies of adherence to MS therapy in clinical practice 
have shown that patients are most likely to discontinue 
therapy within the first 6 months after treatment initiation. 
Discontinuation rates during the first 6 months of treatment 
have been reported to range from 9% to 20%,8,9 although 
abandonment of an MS treatment regimen can happen at any 
time. In one study of patients with relapsing–remitting MS, 
with a mean follow-up duration of 4.2 years, 46% of patients 
stopped treatment over the course of the study.10
Rates of discontinuation of therapy in clinical trials 
tend to be somewhat lower than in clinical practice, perhaps 
reflecting the fact that patients enrolled in trials receive 
more thorough follow up than is usual in everyday practice.8 
In general, clinical trials of DMDs in MS show favorable 
rates of adherence, particularly the more recent trials, which 
routinely employ management strategies to minimize adverse 
events (AEs) and to ensure patients’ compliance with treat-
ment. However, dropout rates from clinical trials may not 
give an accurate picture of long-term adherence to therapy 
in the clinical setting, where the patient and physician may 
elect to change to a different drug, or the patient may choose 
to discontinue therapy altogether. Additionally, disease 
management strategies employed as standard practice vary 
between clinics, and this may cause adherence rates to differ 
between centers.
Barriers to adherence to MS treatment
Disease-related factors
A patient’s subtype of MS may influence their likelihood of 
adherence to therapy. One study, which followed 632 patients 
for a mean period of 47.1 months, found that adherence 
was poorer in patients with secondary progressive MS than 
in those with relapsing–remitting MS. The authors also noted 
that the patients with relapsing–remitting MS who stopped 
therapy were younger than those who remained on treatment, 
had higher levels of initial disability and more active disease, 
and were more likely to be female.11
Cognitive impairment and depression
Cognitive impairment often results from MS,12 and may make 
it difficult for the patient to follow correctly the prescribed 
treatment regimen. Current MS therapies require regular 
administration, and impaired memory function may reduce 
the likelihood of timely administration. Additionally, despite 
efforts to simplify the injection process through the design of 
delivery technology, cognitive dysfunction could also impair 
correct injection technique. However, the impact of cogni-
tive impairment on adherence to MS therapy remains to be 
clarified in studies. Depression is common among patients 
with MS, and may negatively affect adherence. A study of 
patients with MS initiating IFN beta-1b therapy found that 
41% of patients reported new or increased depression within 
6 months of starting treatment. Eighty-six percent of patients 
who received psychotherapy or antidepressant treatment Patient Preference and Adherence 2010:4 
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continued therapy, compared with 38% of patients who 
received no treatment for depression (P = 0.003).13
Efficacy concerns
Perceived lack of efficacy is one of the most commonly 
cited reasons for treatment discontinuation.8,11,14 The disease 
course of MS varies between patients, and while therapy is 
often effective, the individual patient may not fully under-
stand the benefits of remaining on treatment. The effects of 
treatment may not become apparent immediately, which may 
in part explain the high discontinuation rates observed in 
the first few months of treatment. Additionally, the unpre-
dictability of the disease course means it is impossible to 
predict how their MS would affect them were they not on 
treatment, so the true benefit of treatment in the individual 
patient is unclear. Some patients starting MS therapy tend 
to be overly optimistic about the benefits of therapy. Unre-
alistic expectations have been shown to be highly predictive 
of premature discontinuation. Therefore, it is important 
that patients’ expectations are managed prior to treatment 
initiation.9,15 Importantly, if a patient does not adhere to the 
prescribed treatment regimen, they may experience poorer 
outcomes, lose faith in their treatment, and become even 
more likely to be poorly adherent.
Adverse events
AEs associated with MS therapy may also contribute to non-
adherence to treatment regimens. The incidence of AEs asso-
ciated with MS therapy tends to decrease the longer a patient 
is on therapy. Therefore, long-term adherence to treatment 
is more likely to be achieved if patients remain on treatment 
through the initial period when AEs can be particularly prob-
lematic. Management strategies to minimize the impact of 
AEs are therefore imperative to preserve adherence.
One of the most common AEs associated with IFN 
beta therapy is flu-like symptoms.16 These symptoms tend 
to appear early in the treatment course, then diminish in 
frequency and severity with increased time on treatment. 
For example, in the pivotal trial of sc IFN beta-1a, flu-like 
symptoms were reported by 69% of patients receiving IFN 
beta-1a over years 1 to 4, but by only 12% after up to 8 years 
of follow up.17,18
Injection-site reactions (ISRs) are another commonly 
reported AE associated with MS therapies. The incidence 
and severity of such reactions may vary between treatments.8 
Injection-site necrosis can occur with IFN beta treatment, 
and is very rarely seen with glatiramer acetate.19–21 However, 
glatiramer acetate injection can sometimes cause lipoatrophy 
at the application site, leading to, sometimes permanent, 
disfigurement.22,23 Correct injection technique and rotation 
of injection sites can help to avoid ISRs.24
inconvenience and needle phobia
Aside from the AEs associated with MS therapies, some 
patients also find the process of regular self-injection bur-
densome, and adherence can be compromised as a result. 
Furthermore, physical disability and cognitive impairment 
resulting from MS can make self-injection and ability to 
comply with treatment regimens difficult.25 Needle phobia, 
which is experienced by up to 22% of the general population, 
can also be a significant barrier to self-administration of 
parenteral therapies among patients with MS.26 Studies in 
other therapy areas have shown that a complex regimen and 
frequent dosing schedule can be barriers to adherence.27 
Currently, all first-line therapies for MS require parenteral 
administration weekly (in the case of im IFN beta-1a) or 
more frequently. In the case of glatiramer acetate,patients are 
required to inject daily. It may be speculated that patients with 
MS would be more adherent to drugs requiring less-frequent 
administration. Natalizumab is delivered via a monthly 
intravenous infusion. It could be argued that the dosing fre-
quency and the fact that natalizumab is administered during 
a clinic visit could encourage adherence. Conversely, this 
route of administration may be considered inconvenient by 
some patients.
Discontinuation patterns and 
consequences of poor adherence
Discontinuation tends to occur earlier after treatment 
initiation if the reason for stopping therapy is AEs than 
when discontinuation is due to lack of efficacy. In a study 
of discontinuation patterns in patients receiving IFN beta, 
patients who stopped therapy as a result of AEs did so after 
a median period of 13 months on treatment, whereas those 
who discontinued as a result of treatment failure (defined 
as non-reduction in pre-treatment relapse rate and/or sus-
tained increase of Expanded Disability Status Scale score 
of 1 point) did so after a median period of 35 months 
(P = 0.0004; Mann–Whitney test).28
In MS, it is currently unclear precisely what effect the 
degree to which patients adhere to therapy has on clinical or 
magnetic resonance imaging outcomes, but patients who do 
not adhere to therapy are unlikely to receive the full potential 
benefit of treatment,8 and therefore may be at increased risk 
of poorer outcomes. A study that investigated the relationship 
between the duration of gaps in MS treatment regimens and the Patient Preference and Adherence 2010:4 
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incidence of severe MS relapses found that patients who had 
gaps in therapy lasting 90 days had a nearly twofold greater 
probability of experiencing a severe relapse than patients 
with shorter gaps in therapy.29 This shows the importance of 
adherence to prescribed regimens for MS. Potential barriers 
to treatment adherence in MS are summarized in Figure 1. All 
of these issues can affect the patient’s quality of life, whether 
they relate to features of the disease, or to the treatment itself. 
It may be speculated that poor overall quality of life may affect 
the individual patient’s likelihood of adherence to therapy.
Management strategies to enhance 
adherence
Maximizing adherence to MS therapies to improve a patient’s 
chance of gaining the full benefit from their treatment is an 
important therapeutic goal. Patient education is of paramount 
importance in achieving this, as a patient’s commitment to a 
therapeutic regimen may well depend on their understanding 
of their condition, their need for treatment, and the potential 
benefits of treatment.15
As perceived lack of efficacy can be a barrier against 
adherence, patients need to have realistic expectations of 
their treatment, and again, information can enhance the like-
lihood of good adherence. A study that examined patients’ 
expectations of treatment before beginning IFN beta therapy 
found that 57% of patients had unrealistic expectations about 
reduction in relapse rate.9 Although educational procedures 
significantly altered unrealistic expectations, 36% of patients 
still had unrealistic expectations of therapy after education. 
Of those patients who discontinued IFN beta therapy, 64% 
had unrealistically optimistic post-education expectations 
of treatment.9
Patients should be informed of therapeutic options, the 
potential benefits and risks of each treatment and the impor-
tance of adhering to their given treatment regimen. Allowing 
patients to take an active role in treatment decisions may 
make them feel empowered, which, in turn, could enhance 
their motivation to remain adherent. Patients also benefit 
from receiving information about potential side-effects, and 
how these can be managed.15
AEs may occur with MS therapies, but they can be 
managed so as to minimize the impact on the patient’s 
life. As all DMDs for MS require frequent injections, ISRs 
and pain may be experienced. Suitable injection technique 
can minimize these events and thus enhance adherence. 
Appropriate injection procedures include those outlines 
below.
•  Refrigerated medication should be warmed to room 
temperature before administration.
•  Hands should be washed thoroughly prior to injection.
•  The injection site should be thoroughly cleansed but 
completely dry before the injection.
•  Ice should not be applied to the skin before injection, but 
may be used afterwards.
•  The needle should be inserted perpendicularly to the skin 
and completely penetrate the skin.
Depression/
cognitive
impairment
Perceived
lack of
efficacy
Poor
adherence
Reduced
efficacy
Adverse
events
Inconvenience
Needle
phobia
Figure  Factors leading to poor adherence to multiple sclerosis therapy.Patient Preference and Adherence 2010:4 
Optimizing benefit of multiple sclerosis therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
•  For im injections, shorter needles should be used for 
patients with less subcutaneous fat.
•  The patient should avoid smoking.
•  Auto-injector use is recommended.
•  Rotation of injection sites is vital to minimize reactions 
due to repeated, frequent injections.
•  The use of topical steroid preparations is not recom-
mended.
The use of auto-injector devices to administer DMDs 
has been shown to reduce the incidence of ISRs compared 
with manual injection.30 These devices are also convenient 
to use, and may be particularly beneficial for patients with 
poor manual dexterity.31 As needle phobia can be a barrier 
to adherence to injectable therapies,26 a device in which the 
needle is hidden from view may have the additional benefit 
of reducing anxiety and thus improving adherence.
Many patients treated with IFN beta experience flu-like 
symptoms, particularly during the few months after treatment 
is started. Dose titration at initiation of IFN beta treatment 
is commonly employed to minimize the incidence of flu-like 
symptoms. A useful scheme for the titration of IFN beta treat-
ment is to begin with 25% of the full dose for the first week, 
50% in the second, and if this is well tolerated, the full dose 
is given from the third week onwards.16 Concomitant non-
steroidal anti-inflammatory drug (NSAID) treatment, either 
prophylactically or as required, can also help to reduce these 
symptoms.16 Low doses of corticosteroids may be adminis-
tered to patients who do not respond satisfactorily to NSAIDs 
for flu-like symptoms. A randomized study compared the 
efficacy of corticosteroids, ibuprofen, and acetaminophen 
for the control of IFN beta-related flu-like symptoms. The 
three treatments showed a similar degree of efficacy on flu-
like symptoms, although flu-like symptoms immediately 
following injection were less severe in patients treated with 
ibuprofen.32 Another technique for the management of flu-
like symptoms is for patients to administer their therapy in 
the evening, meaning that the majority of acute symptoms 
occur while they are asleep.16
Adherence to MS therapy can be enhanced by providing 
the patient with a support network. Often, the MS nurse is 
well placed to co-ordinate the support network, being the 
central point of contact with the patient once therapy has 
been initiated. MS nurses can provide the patient with infor-
mation on available support services offered by the clinic or 
in the community. Many patients find that self-help groups 
can provide valuable support and information. Additionally, 
the MS nurse can advise the patient on the management of 
symptoms, side-effects, and co-morbidities.
In addition to the care provided by the physician and nurse, 
treatment, information, and support from a wider, multidis-
ciplinary team can enhance further the patient’s adherence to 
therapy.33 The patient and their family and friends are central 
in this care model, with support from the family practitioner, 
physiotherapist, neuropsychologist, and MS societies form-
ing valuable relationships with the patient. Many patients 
report that how they are treated by their care team influences 
their likelihood of following medical recommendations.33 
One study of adherence to IFN beta-1b in 939 patients with 
SPMS found that the highest rates of adherence were achieved 
in clinics where empathetic and less formal relationships 
between patients and caregivers were encouraged.34 Effec-
tive and sensitive working relationships between the patient 
and their support team are an important part of the patient’s 
care. As the disease course of MS is unpredictable, and the 
patient’s attitudes and behavior patterns can be changeable, 
encouraging adherence is a complex issue. The support team 
needs to be aware of the potential barriers to adherence and 
sensitive to the patient’s state of mind in order to support the 
patient with the goal of maintaining adherence.35
The formulation of MS drugs can influence their 
tolerability, and formulation adjustments may serve to 
improve tolerability and so enhance adherence. For example, 
IFN beta-1a for sc injection has been re-formulated, produced 
without fetal bovine serum and without human serum albu-
min as an excipient. A recent 2-year study36 compared data 
on the tolerability and immunogenicity of patients treated 
with the new formulation of sc IFN beta-1a (n = 260) with 
historical data on patients treated with the previous formu-
lation of sc IFN beta-1a in the EVIDENCE (n = 339) and 
REGARD (n = 381) trials. The incidence of ISRs in patients 
receiving the new formulation was 31%, almost three times 
lower than in the EVIDENCE study (86%), and lower than in 
the REGARD study (41%). Levels of immunogenicity were 
lower with the new formulation than in the historical cohort, 
with apparent comparable efficacy. However, it remains to be 
seen whether these improvements in tolerability and immu-
nogenicity will translate into higher adherence rates. A study 
that assessed the immunogenicity and safety of a human 
serum albumin-free formulation of im IFN beta-1a found the 
tolerability profile of the human serum albumin-free formula-
tion similar to that of the original formulation.37
Future directions for the 
enhancement of adherence in MS
There are several strategies being explored that may prove to 
enhance adherence to MS therapies. These include advances Patient Preference and Adherence 2010:4 
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in delivery technology, improved patient education and 
support programs and alternative routes of administration. 
Perhaps the most important advance in MS treatment that is 
anticipated to significantly improve adherence to long-term 
treatment will be the availability of orally administered 
drugs. In terms of adherence, oral drugs have a potential 
advantage over injected therapies in that needle phobia and 
injection-related AEs will not be an issue, making treatment 
available to patients with MS who are unable, or unwill-
ing, to receive regular injections. Nonparenteral routes 
of drug administration can also be expected to enhance 
adherence.1 In other therapy areas, such as oncology and 
diabetes, patients prefer receiving their medication in the 
form of tablets or an inhaled preparation, rather than as 
injections.38–40 Additionally, oral or inhaled medications 
are associated with heightened levels of patient satisfaction 
with their treatment.38,41 Therefore, with the more convenient 
administration route, oral MS therapies may be expected to 
improve rates of adherence compared with those found with 
injected drugs.
Although the development of new oral agents for the 
treatment of MS is an important step in improving adherence 
to MS therapy, oral administration may not entirely solve the 
problem of poor adherence. The example of osteoporosis 
treatment clearly shows that frequency of dosing can greatly 
influence the adherence to oral therapies. Studies show that 
persistence with weekly oral bisphosphonate therapy is 
substantially greater than with a daily regimen, although 
still not optimal. Additionally, patient surveys show that the 
majority of patients prefer a weekly regimen to daily, with a 
once-monthly regimen being the most popular.42 Studies in 
other therapy areas have also shown that simpler43,44 and less 
frequent45,46 dosing produces greater adherence than more 
frequent administration.
Several oral agents for the treatment of MS are currently 
being studied in Phase III trials (Table 1). Laquinimod, 
a derivative of linomide, alters dendritic cell responses 
and promotes a shift to Th2 immunity.47 BG-12 is a 
second-generation fumaric acid derivative, which has 
shown promising results on MRI measures of MS in 
Phase II studies.48 Fingolimod (FTY720) is a sphingosine-
1-phosphate agonist that was originally investigated 
for the prevention of renal transplant rejection. It is an 
immunosuppressive agent that induces lymphopenia by 
sequestering lymphocytes into secondary lymph nodes. 
Via this mechanism it prevents T cells from crossing the 
blood-brain barrier and invading the CNS. Fingolimod 
preferentially depletes B cells and may have vasopro-
tective properties and neuroprotective effects. Phase II 
trials of fingolimod in patients with MS showed efficacy 
in MRI and clinical measures.49 Preliminary results of a 
Phase III study indicate that the efficacy of fingolimod is 
superior to that of im IFN beta-1a for relapse rate.50 Leflu-
nomide is used in the treatment of rheumatoid arthritis. 
Its active metabolite, teriflunomide, reduced the number 
of MRI lesions in patients with MS in Phase II trials. It 
causes the selective depletion of B and T cells by inhibit-
ing the synthesis of pyrimidine nucleotides.51 Cladribine 
is a small molecule, which acts as a prodrug: a deoxy-
adenosine analogue immunomodulator that is resistant 
to deamination by the enzyme adenosine deaminase. 
Activation of cladribine in specific cell types results in 
preferential reduction of lymphocyte B and T subtypes,52,53 
both of which are involved in MS pathogenesis,54,55 with 
relatively minor effects on other hematological and 
immune cell types.52,56–58 Cladribine tablets therapy was 
developed following encouraging clinical trial experi-
ence with parenteral cladribine in MS.52,56,59 The sustained 
Table  Oral agents currently in Phase iii trials for multiple sclerosis
Agent Molecule type Therapeutic target Current/previous use Expected dosing regimen
Fingolimod Partial sphingosine- 
1-phosphate receptor agonist
Lymphocyte trafficking renal transplantation 
(failed Phase iii trials)
5.0 or 1.25 mg daily
Laquinimod Derivative of linomide 
(roquinimex)
Prevention of T-cell activation Oncology (antiangiogenic 
agent)
0.6 mg daily
BG-12 Fumaric acid derivative Prevention of T-cell activation Psoriasis (approved in 
Germany)
720 mg daily
Teriflunomide Active metabolite of 
leflunomide
Lymphocyte antiproliferation 
agent
rheumatoid arthritis 7.0 or 14.0 mg daily
Cladribine Purine nucleoside analog 
pro-drug
Preferential reduction of 
T and B lymphocyte subtypes
Hairy cell leukemia and 
lymphoma
Short-course annual dosing 
regimen (3.5 mg/kg or 
5.25 mg/kg over 96 weeks)Patient Preference and Adherence 2010:4 
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effects on T and B cells has allowed for the development 
of cladribine tablets using a short-course annual dosing 
regimen. This may mean that patients need to take tablets 
for 10 or 20 days per year. Cladribine tablets recently 
became the first orally administered investigational treat-
ment for MS to complete a 2-year Phase III pivotal study in 
which it demonstrated rapid and significant improvements 
in clinical outcome measures, including reductions in 
relapse rates and the risk of developing 3-month sustained 
disability progression relative to placebo in patients with 
relapsing–remitting MS.60–62
Should one or more of these oral therapies in development 
be approved for the treatment of MS, it may be speculated 
that their benefits would lead to higher levels of treatment 
adherence currently seen with parenteral treatments. While 
a change in administration route is unlikely to completely 
solve the problem of poor adherence, the advent of oral 
therapies represents a significant milestone in the care of 
patients with MS.
Conclusions
Adherence to treatment regimens is essential for patients to 
gain the full benefit of their therapies.1 Although the impact of 
non-adherence to MS therapies has not been widely assessed, 
it is reasonable to assume that poor adherence to MS drugs 
results in poorer outcomes. It has been shown that long 
interruptions in MS therapy confer a higher risk of severe 
relapse.29 As with other chronic diseases such as cancer and 
diabetes, nonadherence and poor adherence to therapy are 
common in MS, and improving adherence should be recog-
nized as an important treatment goal in its own right. Many 
factors can cause patients to discontinue treatment, including 
treatment-related AEs and patient perception of lack of 
efficacy. Where possible, these should be addressed through 
patient education and support, and strategies to maximize 
drug tolerability to improve adherence. Appropriate measures 
to enhance adherence are summarized below.
•  Adherence must be considered an important modifier of 
the efficacy of long-term treatment.
•  The management of patients’ expectations should be 
central in the process of treatment of patients with MS.
•  Patients should be trained in appropriate injection tech-
nique (such as rotation, self-injection).
•  Patients must be informed of the potential side-effects 
and on the correct management of the latter.
•  Specific work must be done with non-adherent patients, 
and the possibility of switching to a different therapy, if 
appropriate, should be discussed.
Oral therapies currently in development also have the 
potential to improve adherence: the absence of ISRs and ease of 
administration may make these treatments more acceptable to 
patients, particularly if the tablet burden is low.
While suboptimal adherence to MS therapies remains a 
problem, adherence can be enhanced by various strategies. 
Future developments in drug and administration technology 
may be expected to further improve adherence, and therefore 
patient outcomes.
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